ARGXargenx SE
Is the price fair?
Modest expectations priced in. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for ~24% a year FCF growth. The price demands less than its three-year revenue growth of 112% a year, expectations look modest.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What ARGX's price assumes
argenx SE trades at 42.2× earnings against 18.8× for the median Biotechnology name, more expensive than its own group.
Trailing P/E · Biotechnology median 18.8 · 2.24× the median: the market pays up for this one
- Price / sales
- 8.21
Price / sales · as of 2025-Q4
- Free cash flow yield
- 1.2%
Free cash flow yield · Biotechnology median 3.6%
- Growth the price implies
- +24%
Growth the price implies · The price pays for +24% free cash flow growth a year for a decade; revenue has grown +112% a year over the last three.
Details›
- Price / bookas of 2025-Q4
- 7.11
- Healthcare median P/E509 names
- 26.2
- Biotechnology median P/E244 names
- 18.8
- Free cash flow, trailing twelve months
- $679M
- Market capitalisation
- $55.5B
- 3-year revenue growth
- +112%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.